The International Lymphoma Study Group published recently a classification. 2 According to this classification, our patient presented histiocytic sarcoma defined by CD68 þ and CD1aÀ. Owing to systemic involvement, the diagnosis was consistent with 'malignant hystiocytosis'. Interestingly, of the 18 cases of granulocytic sarcoma reported by Pileri, three had systemic presentation of the disease and two of whom previously presented acute lymphoblastic leukemia or myelodysplasia. Most histiocytic sarcomas are treated as high-grade non-Hodgkin's lymphomas but the prognosis seems very poor. 1, 3 The pathogenesis of the histiocytic sarcomas is not well understood. In the case reported here, the etiologic role of the previous ALL and transplantation, or the high immunosuppression level using novel drug as MMF is unknown. The EBV genome was expressed neither by blood cells or by tumor cells. The patient presented a 100% donor chimerism in blood but the exact tumor origin, donor or recipient, remains unknown. Three other cases of histiocytic sarcoma following therapy for lymphoblastic neoplasms were published in one adult and two children. Neither had been transplanted before the diagnosis of histiocytic sarcoma. 4 Nevertheless, the histiocytic sarcoma observation is too rare to conclude about the role of previous hematological malignancy, transplantation or intensive immunosuppression on its pathogenesis.
All three patients reported by Soslow received intensive chemotherapy as histiocytic sarcoma treatment and two were alive with disease at the time of last follow-up. The very precarious clinical status of our patient at the time of histiocytic sarcoma diagnosis associated with the relative recent bone marrow transplantation (9 months) did not permit the use of aggressive chemotherapy. Even vinblastine has not been tolerated more than a few weeks. After DLI failed, we did a trial of thalidomide therapy. Although thalidomide was withdrawn in the early 1960s because of its severe teratogenic effects, it is being used again for the past few years to treat a variety of diseases such as inflammatory disease (as Crohn's disease or Behcet's syndrome) in addition to a variety of cancers, such as colon cancer and glioma and, in hematology, multiple myeloma as reported by Rajkumar et al. 5 In hematology, thalidomide is also used for severe, extensive and refractory cutaneous chronic GVHD that resemble sclerodermia. A recent review reported the use of thalidomide in pediatric patients and concluded that 'it should be used as a last resort when all other therapies fail'. 6 Thalidomide presents different potential mechanisms of antitumoral activity: angiogenic properties by vascular endothelial growth factor and basic fibroblast growth factor inhibition, cytokine regulation (inhibition of TNF-a production, stimulation of IL-2 production), apoptosis induction and possibly direct cytotoxicity effect by free radical-mediated oxidative DNA damage. 5, 7, 8 Most of thalidomide side effects such as drowsiness, weakness, dizziness, tingling, numbness or skin rash, appear dose related, and only 10-30% of patients must discontinue the treatment because of side effects. Neuropathy is observed more frequently in women and older patients. In this case, after almost 3 years of thalidomide use, the boy is well without severe side effects. Nevertheless, complete remission has not been obtained and several bone sites of disease remain stable. Different therapeutic questions remain to be discussed: how long thalidomide must be continued? What kind of positive effect is expected? Is the patient now able to receive aggressive chemotherapy in order to cure THL and if so, what kind of chemotherapy?
This case report confirms the rare but possible development of histiocytic sarcoma after a lymphoblastic neoplasm and shows the potential efficiency of thalidomide in histiocytic cell proliferation and its good tolerance in a single child. with HCL. There are also several reports suggesting an association with systemic immunologic disorders such as scleroderma, polymyositis and various vasculitides. Among the vasculitides, polyarteritis nodosa represents the most frequently associated disorder, with 18 reports in the medical literature to date. It has been suggested that a common membrane antigen occurs in leukemia cells and vascular endothelium, leading to a vasculitis via a crossreacting antibody. 4 Four cases of scleroderma occurring with HCL have been previously described in the literature. A humoral or cell-mediated response initiated by leukemia cells is thought to be responsible. Alternatively, fibrosis triggered by hairy cells in the bone marrow may occur in an extramedullary distribution, mimicking the clinical symptoms of scleroderma. 5 To date, two reports exist describing a concomitant diagnosis of HCL and sarcoidosis. 6, 7 We now report a third case and suggest a possible association of the two disorders.
A 71-year-old patient developed tender skin nodules in the right lower extremity followed by bilateral ankle edema and then development of erythema nodosum in the left lower extremity in November 2000. A biopsy obtained 1 month later showed a noncaseating inflammatory infiltrate with multinucleated giant cells without evidence of caseating necrosis. A chest roentgenogram showed no lymphadenopathy. The patient underwent rheumatologic evaluation that showed a normal angiotensin converting enzyme level, a positive antinuclear antibody, and otherwise negative serologies. Bronchoscopic biopsy in February 2002 again showed noncaseating granuloma consistent with a diagnosis of sarcoidosis (Figure 1) . The patient was then treated with high-dose corticosteroids although she soon developed generalized osteopenia and a pelvic fracture.
In May 2002, the patient developed asymptomatic leukopenia. Blood examination showed WBC 2.75 Â 10 9 with 43.4% segmented neutrophils, 38.8% lymphocytes and 15.3% monocytes, hemoglobin 12.9 g/dl and platelets 125 Â 10 9 /l. Peripheral smear demonstrated reduced leukocytes with atypical lymphocytes displaying cytoplasmic projections (Figure 2 ). The bone marrow aspirate showed progressive maturation of all lineages with an M:E ratio of 0.6, erythroid preponderance with a myeloid left shift, and TRAP-stain positivity in numerous cells. Biopsy sections showed a variable cellularity (15-50%) with several aggregates of abnormal lymphoid cells with round, central nuclei and clear cytoplasm. Immunophenotyping was negative for bcl-1 and bcl-6 and positive for bcl-2, CD3, CD20 and CD68.
Flow cytometry was performed on a peripheral blood specimen with gating for cells of lymphoid origin (approximately 25% of total cells). T cells comprised 70% of the specimen and B cells 14%. Table 1 summarizes the results of flow cytometry.
Shortly after the development of osteoporosis, corticosteroid therapy was tapered. Following the diagnosis of HCL, the patient received 1 week of intravenous chemotherapy with the purine analogue cladribine (2-chlorodeoxyadenosine, 0.09 mg/ kg/day). A repeated TRAP stain on a peripheral smear in July 2002 was negative. The patient was seen in February 2003. Blood examination at this time showed continued remission, with WBC 4.08 Â 10 9 with 76.5% segmented neutrophils and 10.8% monocytes, hemoglobin 11.8 g/dl and platelets 210 Â 10 9 /l. Coexpression of B-cell marker CD19 with CD11c, CD25, CD103 and FMC7 as well as morphologic features on bone marrow and peripheral smear strongly suggest a diagnosis of hairy cell leukemia arising 18 months after the diagnosis of sarcoidosis. Two disorders in particular bear histologic resemblance to hairy cell leukemia (splenic lymphoma with villous lymphocytes, SL VL; and HCL-variant, HCL-V), but these typically lack expression of the aforementioned hairy cell surface antigens. 8 In two previous reports of HCL with sarcoidosis, the diagnosis of HCL occurred 12 years following the diagnosis of sarcoidosis, 6 and in the other patient the diagnoses were concurrent. 7 In the prior reports, it was hypothesized that defects in T lymphocytes allowed for B-cell proliferation into both HCL and sarcoid. In the setting of sarcoidosis, T cells participate in antigen recognition and amplification of local cellular immune responses. This immune response is achieved through the Figure 1 Bronchoscopic biopsy specimen from the patient demonstrating presence of noncaseating granuloma consistent with sarcoidosis.
Figure 2
Peripheral smear from the patient demonstrating presence of a hairy cell (arrow). Note the presence of fine, outward cytoplasmic projections. 9 Several studies also implicate the role of the same cytokines in the development of HCL. More specifically, activation of hairy cells involves expression of the autoregulated IL-2 receptor (the CD25 surface antigen represents the achain). 10 Thus, alteration of the cellular microenvironment by the defective T-cells of sarcoidosis may lead to development of HCL.
The presence of an as yet unexplained oligoclonal T-cell proliferation in HCL also bears resemblance to sarcoidosis. In sarcoidosis, patients possess a wide variety of oligoclonal T-cell lines, theoretically representing responses to separate epitopes. 9 This scenario gives rise to the possibility that certain epitopes that trigger the inflammatory changes of sarcoidosis may serve as exogenous stimuli for hairy cell activation. More likely, the presence of oligoclonal T cells in both diseases supports the role of local cytokine mediators released in sarcoidosis in the activation of hairy cells, as previously described.
Alhough not concordant with the temporal pattern described in one of the case studies referenced, the development of sarcoidosis as a sequela of HCL could also be considered. Several of the antigens restricted to hairy cells, such as CD11c and CD103, have been associated with the activation of both lymphoid and nonlymphoid cell types. 8 This serves as a rationale for the frequently reported association of nonHodgkin's lymphoma and HCL. Among the nonlymphoid lineages activated are natural killer (NK) cells, which participate directly in the nonspecific inflammatory response triggered by T cells. 8 Thus, sarcoidosis may be induced either directly through hairy cell antigen-mediated activation of T cells or indirectly through promotion of the nonspecific inflammatory response.
A more concrete association of sarcoidosis and HCL will require examination of a larger number of patients. However, the interplay of these two disorders with respect to T-cell function and subsequent cytokine-mediated responses does appear to have a molecular basis. With further study, this interplay may serve to explain the relationship between numerous other lymphoproliferative and systemic immunologic diseases. 
